Hearing Loss Trial, Recruiting (NCT05641441)

Hearing Loss Trial, Recruiting NCT05641441 Sponsor: University Hospital, Geneva Condition: Hearing Loss

Printed from Voxsanity (voxsanity.com.au) — NCT05641441 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Hearing Loss

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who are 18 years of age or older
People who have a non-cancerous ear tumour called a vestibular schwannoma (VS) on one side only, and whose medical team has already recommended either a type of focused radiation treatment (called stereotactic radiosurgery, or SRS) or a "watch and wait" approach using MRI scans
People who are willing to participate and have agreed to take part by signing a consent form

Who may not be able to join:

People who have previously had surgery or any radiation treatment for their vestibular schwannoma (including stereotactic radiosurgery)
People who have been diagnosed with a genetic condition called neurofibromatosis type II
People who already have very severe hearing loss in the affected ear, based on specific hearing test results measured at their first assessment (confirm with trial site)
People who have previously had surgery on the middle ear on the affected side
People who are currently taking part in another clinical trial involving an experimental drug or treatment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 0223728244

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05641441

Sponsor: University Hospital, Geneva

Phase: Not Applicable

Status: Recruiting

Condition: Hearing Loss

Trial contact: 0223728244

More information: https://clinicaltrials.gov/study/NCT05641441

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who are 18 years of age or older
People who have a non-cancerous ear tumour called a vestibular schwannoma (VS) on one side only, and whose medical team has already recommended either a type of focused radiation treatment (called stereotactic radiosurgery, or SRS) or a "watch and wait" approach using MRI scans
People who are willing to participate and have agreed to take part by signing a consent form

Who may not be able to join:

People who have previously had surgery or any radiation treatment for their vestibular schwannoma (including stereotactic radiosurgery)
People who have been diagnosed with a genetic condition called neurofibromatosis type II
People who already have very severe hearing loss in the affected ear, based on specific hearing test results measured at their first assessment (confirm with trial site)
People who have previously had surgery on the middle ear on the affected side
People who are currently taking part in another clinical trial involving an experimental drug or treatment

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University Hospital, Geneva

Registry

ClinicalTrials.gov

Start date

24 January 2023

Est. completion

15 November 2030

Where this trial is recruiting

🇨🇭 Switzerland

Primary endpoints

Change of Pure Tone Average from baseline; Change of Word recognition score from baseline

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov